Editorial Videos

Gen Li, founder and president of Phesi, discusses how the rise of GLP-1 medications is impacting how various diseases are treated beyond the ones the medications are specifically designed to treat.

Craig Thompson, CEO of Cerevance touches on the NETSseq platform and how it shapes Cerevance's approach to the drug discovery strategy.

Craig Thompson, CEO of Cerevance discusses the key scientific and clinical insights that lead to Cerevance's pursuit of Solengepras.

The MFN executive order may result in the US losing its place as the friendliest market for innovation.

While the MFN executive order targets drug companies for drug prices, Peter Rubin discusses how health plans also play a large role in this area.

Ryan Quigley, CEO of Inizio, explains the impact of advancements and innovations and how they’re making pharma more personalized.

Peter Rubin discusses how effective President Trump’s executive order could actually be against the factors that dictate drug pricing.

Aside from pricing changes, the impacts that MFN could have on the US market could have global reverberations.

Ryan Quigley, CEO of Inizio, details the current usage of AI and other advanced technologies.

Madeline Verbeke, Senior Clinical Advisor, MMIT, touches on changing the treatment paradigm for obesity & MACE indications, important considerations for translating cardiovascular benefits in injectable GLP-1s, and clinical potential for oral GLP-1s.

In order to enforce MFN, regulatory agencies must navigate the complex process of determining a drug’s true value.

Alongside regulations from the IRA, oncology R&D is set to face unique challenges when MFN is enforced.

Madeline Verbeke, Senior Clinical Advisor, MMIT, touches on injectable and oral GLP-1's impact on the clinical landscape, and the clinical and scientific hurdles oral GLP-1 formulations need to overcome to gain comparable traction.

Rob DeWig, VP of Healthcare Sales at Inmar, touched on the current operational challenges that health system pharmacies face.

Peter Rubin discusses how the industry is an ecosystem and each of the parts will feel the impact differently.

Rob DeWig, VP of Healthcare Sales at Inmar, touches on how access to 25% of benchmarking data from national pharmacy claims change for Premier Members.

Ryan Quigley, CEO of Inizio, explains how AI, personalized medicine, and GLP 1s are shaping commercialization trends.

Ryan Quigley, CEO of Inizio, discusses how advancement in science are changing the pace of commercialization.

Rob DeWig, VP of Healthcare Sales at Inmar, touches on looming DSCSA enforcement and the impact of Inmar's reconciliation tools.

Rob DeWig, Vice President of Healthcare Sales, Inmar, touches on the impact of Inmar and Premier's expanded agreement on the broader healthcare and pharmacy ecosystems.

Ryan Quigley, CEO of Inizio, discusses how his experience as Chief Operating Officer shaped his journey to CEO.

It seems there is no text provided for summarization. Please provide the text you'd like summarized, and I'll be happy to help!

Helen Sabzevari, PhD, president and CEO of Precigen, explains how Papzimeos transforms clinical practice by establishing the first FDA-approved standard of care for recurrent respiratory papillomatosis (RRP), shifting treatment from repeated surgeries to an immunotherapy that addresses the root HPV infection, with future plans to expand into pediatric populations and redosing strategies.

Helen Sabzevari, PhD, president and CEO of Precigen, reflects on how Papzimeos sets an important precedent for rare disease therapies, with its broad FDA label for all adult patients with recurrent respiratory papillomatosis (RRP) highlighting the potential for earlier intervention to prevent irreversible damage and establish new standards of care.

Helen Sabzevari, PhD, president and CEO of Precigen, discusses the FDA’s decision to grant full approval to Papzimeos without requiring a confirmatory trial, highlighting how strong safety, efficacy, and durability data supported a broad label for all adult patients with recurrent respiratory papillomatosis (RRP).

Helen Sabzevari, PhD, president and CEO of Precigen, explains how Papzimeos, developed using the company’s AdenoVerse platform, became the first FDA-approved therapy for adult patients with recurrent respiratory papillomatosi.

In this video interview, Helen Sabzevari, PhD, president and CEO of Precigen, discusses the background of Recurrent Respiratory Papillomatosis treatments that led to Papzimeos becoming the first FDA-approved therapy for Recurrent Respiratory Papillomatosis.

In today’s Pharmaceutical Executive Daily, we review the wave of pharmaceutical layoffs shaping 2025, highlight the latest Pharm Exec Top 50 company rankings, and cover BioNTech and Duality Biologics’ clinical trial success with BNT323.

Marc Stapley, CEO of Veracyte, reviews upcoming developments in the diagnostic space.

Marc Stapley, CEO of Veracyte, explains how investors are reacting to recent advancements in cancer care.